EHA2021 – Update-in-Hematology - BeiGene Medical Europe

EHA2021 – Update-in-Hematology

 VIDEO   1:03:33   06/2021

Rationale and Role of BTK Inhibition as a Treatment Strategy for Patients with Indolent B-Cell Lymphomas

Background and Insights on the Use of BTK Inhibitors Now and in Future in WM and MZL

 

Christian Buske
Welcome & Introduction

Steven Treon
Rationale for Targeting TLR/BCR in Indolent Lymphomas -
Role of BTK inhibition as a Treatment Option for WM and MZL

Shirley D'Sa
WM and MZL - disease, diagnosis, role of TLR/BCR pathway

Christian Buske
WM ‒ SoC and Role of BTK inhibitors now and in future

Alessandra Tedeschi
MZL ‒ SoC and Role of BTK inhibitors now and in future

Christian Buske
Panel Discussion and Audience Q&A

Rating

Rate this resource